Author

E. DiMango

Observed institution: Columbia University Irving Medical Center

OpenAlex ID: A5033604123

WS13.3 Efficacy and safety of ataluren in patients with nonsense-mutation cystic fibrosis not receiving chronic inhaled aminoglycosides: the international, randomized, double-blind, placebo-controlled Ataluren Confirmatory Trial in Cystic Fibrosis (ACT CF)

2017 · M.W. Konstan, E. DiMango, et al. · Journal of Cystic Fibrosis · 2

574 Determining the minimal clinically important difference for the 22-question SinoNasal Outcome Test (SNOT-22) in people with cystic fibrosis

2022 · D. Beswick, J. Overdevest, et al. · Journal of Cystic Fibrosis · 1

Long-term safety and efficacy of vanzacaftor/tezacaftor/deutivacaftor in people with cystic fibrosis aged 12 years and older: 96-week interim analysis from an open-label extension study

2026 · R.W. Linnemann, A. Trimble, et al. · Journal of Cystic Fibrosis

52 Participation in interventional drug trials of minority populations at an urban adult cystic fibrosis center

2022 · M. Ycaza, C. Keating, et al. · Journal of Cystic Fibrosis

Works count: 4

Citation count: 3

H-index: 1

I10-index: